AAVL Insider Trading Activity and SEC Form 4 Filings
AAVL insider trading summary
No open-market insider purchases or sales of Avalanche Biotechnologies, Inc. (AAVL) have been reported on SEC Form 4 in the past 12 months.
Latest AAVL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 22, 2015 | Steven Daniel Schwartz | Director | Sell | $446K (11,679 @ $38.16) |
| May 22, 2015 | Steven Daniel Schwartz | Director | Sell | $202K (5,196 @ $38.88) |
| May 21, 2015 | Mehdi Gasmi | VP, Pharmaceutical Development | Sell | $19K (500 @ $38.87) |
| May 19, 2015 | Mark S. Blumenkranz | Director | Sell | $37K (1,000 @ $36.91) |
| May 8, 2015 | Steven Daniel Schwartz | Director | Sell | $570K (17,250 @ $33.05) |
| May 7, 2015 | Mehdi Gasmi | VP, Pharmaceutical Development | Sell | $17K (500 @ $33.28) |
| May 5, 2015 | Thomas W. Chalberg | Chief Executive Officer | Sell | $750K (25,000 @ $30.00) |
| May 4, 2015 | Linda Bain | Chief Financial Officer | Sell | $79K (2,500 @ $31.59) |
| May 4, 2015 | Paul Wachter | Director | Sell | $37K (1,192 @ $30.87) |
| May 4, 2015 | Hans Hull | SVP, Business Operations | Sell | $154K (5,000 @ $30.87) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.